US20260108539
2026-04-23
Human necessities
A61K31/658
The document outlines a novel treatment for knee osteoarthritis using a cannabinoid-based nanoplatform. The composition is designed for intra-articular injection and includes phytocannabinoids like CBG and CBC, combined with hyaluronic acid, type II collagen, and calcium gluconate. These ingredients are embedded within a nanoplatform to enhance bioavailability and ensure controlled release in the synovial space. This treatment aims to alleviate symptoms such as joint pain, stiffness, reduced mobility, and inflammation, while also addressing the underlying causes of osteoarthritis.
Cannabinoids in the composition interact with CB1 and CB2 receptors, modulate cytokines, inhibit NF-ΞΊB, and activate TRPV1 receptors, providing a potent anti-inflammatory effect. The formulation is designed to halt cartilage degeneration, reduce pain, and slow the progression of osteoarthritis. The production process employs nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration to ensure both efficacy and safety.
The technical field of this disclosure relates to therapeutic compositions incorporating cannabinoids for the management of knee osteoarthritis. Osteoarthritis is a prevalent joint disease, particularly affecting the knee, and is a leading cause of disability and healthcare costs. Current treatments often fail to comprehensively target both inflammation and the degeneration of bone and cartilage. This new composition offers a safer, more effective alternative by modulating the endocannabinoid system and utilizing advanced nanoplatforms.
The disclosure presents three main embodiments: a cannabinoid-based composition, a method of treatment, and a manufacturing method. The composition includes cannabinoids and additional active agents like structural proteins and mineral supplements, designed for intra-articular administration. The method of treatment involves quarterly injections to relieve symptoms and mitigate health risks, while the manufacturing method ensures consistent formulation and optimized bioavailability, enhancing therapeutic efficacy.
This therapeutic approach specifically addresses the clinical needs of knee osteoarthritis patients, aiming to alleviate symptoms and slow disease progression. It offers an innovative, evidence-based intervention that improves quality of life and reduces long-term health risks. By targeting symptomatic relief and the pathophysiological progression of osteoarthritis, the treatment provides a safer alternative to conventional therapies, enhancing joint function and maintaining bone health.